Bausch + Lomb acquire Technolas Perfect Vision

Article

Bausch + Lomb will purchase all outstanding shares of leading ophthalmic laser company Technolas Perfect Vision.

Bausch + Lomb will purchase all outstanding shares of leading ophthalmic laser company Technolas Perfect Vision.

The companies, who entered into a co-promotion agreement in September 2011, will close the acquisition deal by the end of January 2013.

In earlier collaborations the companies have heavily promoted and further advanced the VICTUS femtosecond laser. The last twelve months has seen the VICTUS platform receive marketing approval from authorities in Europe and the US.

Dr Kristian Hohla, CEO of Technolas Perfect Vision, stated, "Our systems for refractive and cataract procedures complement Bausch + Lomb’s surgical portfolio and will help accelerate our expansion into the faster growing segments of the ocular surgery market. Together, we’ve proven our ability to introduce and market the highly innovative and differentiated VICTUS Femtosecond Laser Platform, and we look forward to working with our Bausch + Lomb colleagues to further advance ocular surgery using other laser-based technologies.”

John Barr, executive vice president and president of Bausch + Lomb Surgical, commented, "Our goal is to provide a compelling choice of products to fit the specific needs of their practice and patients. We intend to continue to invest in development and clinical programs that build upon their strong leadership position in laser-based surgical platforms. We look forward to working with Kristian and his team to provide physicians with systems that improve a wide range of sight-enhancing surgeries."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.